Literature DB >> 18343619

Analytical methodologies for the determination of cisplatin.

M Espinosa Bosch1, A J Ruiz Sánchez, F Sánchez Rojas, C Bosch Ojeda.   

Abstract

cis-Diamminedichloroplatinum(II) (cisplatin) is a important chemotherapeutic drug for cancer treatment since 1978. Unfortunately, because of the severe side-effects like nephrotoxicity, ototoxicity, etc., they are administered in small doses at low concentration establishing the maximum limit dosage to 100 mg/m(2) (21 days). A variety of analytical methods have been proposed for the determination of cisplatin in biological fluids and tissues that permit the accurate determination at or below the part per billion level in the native sample. The purpose of the current review is to provide a systematic survey of the latest analytical techniques for the determination of cisplatin in biological samples.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343619     DOI: 10.1016/j.jpba.2008.01.047

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  9 in total

1.  Preclinical imaging characteristics and quantification of Platinum-195m SPECT.

Authors:  E A Aalbersberg; B J de Wit-van der Veen; O Zwaagstra; K Codée-van der Schilden; E Vegt; Wouter V Vogel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-11       Impact factor: 9.236

2.  Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.

Authors:  Michael Groessl; Yury O Tsybin; Christian G Hartinger; Bernhard K Keppler; Paul J Dyson
Journal:  J Biol Inorg Chem       Date:  2010-03-07       Impact factor: 3.358

3.  From a Chemotherapeutic Drug to a High-Performance Nanocatalyst: A Fast Colorimetric Test for Cisplatin Detection at ppb Level.

Authors:  Valentina Mastronardi; Mauro Moglianetti; Edoardo Ragusa; Rodolfo Zunino; Pier Paolo Pompa
Journal:  Biosensors (Basel)       Date:  2022-05-30

4.  In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles.

Authors:  Shanthi Ganesh; Arun K Iyer; Florence Gattacceca; David V Morrissey; Mansoor M Amiji
Journal:  J Control Release       Date:  2013-10-22       Impact factor: 9.776

5.  Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer.

Authors:  Lihua Cheng; Chengmeng Jin; Wen Lv; Qiuping Ding; Xu Han
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

6.  Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry.

Authors:  Denis V Navolotskii; Natalya B Ivanenko; Nikolay D Solovyev; Elena I Fedoros; Andrey V Panchenko
Journal:  Drug Test Anal       Date:  2015-06-10       Impact factor: 3.345

7.  Determination of Liposomal Cisplatin by High-Performance Liquid Chromatography and Its Application in Pharmacokinetic Studies.

Authors:  Alfonso Toro-Córdova; Fabricio Ledezma-Gallegos; Laura Mondragon-Fuentes; Rafael Jurado; Luis A Medina; Jazmin M Pérez-Rojas; Patricia Garcia-Lopez
Journal:  J Chromatogr Sci       Date:  2016-03-24       Impact factor: 1.618

8.  Revealing chemical processes and kinetics of drug action within single living cells via plasmonic Raman probes.

Authors:  Shan-Shan Li; Qi-Yuan Guan; Gang Meng; Xiao-Feng Chang; Ji-Wu Wei; Peng Wang; Bin Kang; Jing-Juan Xu; Hong-Yuan Chen
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

9.  Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation.

Authors:  Laura Astolfi; Sara Ghiselli; Valeria Guaran; Milvia Chicca; Edi Simoni; Elena Olivetto; Giorgio Lelli; Alessandro Martini
Journal:  Oncol Rep       Date:  2013-02-06       Impact factor: 3.906

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.